{"entity":{"id":"nct07241936","kind":"trial","name":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SYS6010 in advanced solid tumours, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., now recruiting.","summary":"A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07241936 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 444 participants planned, started 2025-11-13 and due to reach its primary completion in 2027-10-30. Interventions recorded: sirolimus (albumin-bound), DP303c, SYS6043, SYS6002 and SYS6010.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07241936","url":"https://clinicaltrials.gov/study/NCT07241936"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sys6010"],"companies":["cspc"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07241936","phase":"1/2","setting":"A Phase Ib/II Clinical Trial on the Safety and Efficacy of Sirolimus (Albumin-bound) Combined With Different ADCs in Patients With Advanced Solid Tumors","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","enrolled":444,"outcomes":[]},"route":"/trials/nct07241936/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"sys6010","kind":"drug","name":"SYS6010","route":"/drugs/sys6010/"}],"company":[{"id":"cspc","kind":"company","name":"CSPC Pharmaceutical Group","route":"/companies/cspc/"}]}}